sitagliptin + Comparator: glimepiride + open-label metformin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus, Non Insulin Dependent
Conditions
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
May 1, 2008 → Oct 1, 2009
NCT ID
NCT00701090About sitagliptin + Comparator: glimepiride + open-label metformin
sitagliptin + Comparator: glimepiride + open-label metformin is a phase 3 stage product being developed by Merck for Type 2 Diabetes Mellitus, Non Insulin Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00701090. Target conditions include Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00701090 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus, Non Insulin Dependent